Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation

Background: Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Hematol Oncol Stem Cell Res
Autors principals: Carvalho, Franceli Ramos, Zuckermann, Joice, Paz, Alessandra, Fischer, Gustavo, Daudt, Liane Esteves, Rigoni, Lisandra Della Costa, Silla, Lúcia, Fogliatto, Laura, de Castro, Simone Martins, Pilger, Diogo André
Format: Artigo
Idioma:Inglês
Publicat: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5338279/
https://ncbi.nlm.nih.gov/pubmed/28286612
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars